Cunniff James L. 4
4 · Electromed, Inc. · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Electromed (ELMD) CEO James L. Cunniff Exercises Options, Sells Shares
What Happened
James L. Cunniff, CEO, President and Director of Electromed, exercised 9,700 shares via option conversion (exercise price $17.25, total cost $167,325) on June 8, 2026, and sold the 9,700 shares in multiple open-market transactions the same day for aggregate proceeds of about $354,096. The filing shows a derivative conversion entry for 9,700 shares at $0 (reflecting the option-to-stock conversion) and three sale entries (7,003; 1,671; 1,026 shares) at weighted-average prices noted below.
Key Details
- Transaction date: June 8, 2026; Form 4 filed June 9, 2026 (appears timely).
- Option exercise: 9,700 shares at $17.25 per share; total exercise cost $167,325.
- Sales (open market): total 9,700 shares sold for combined proceeds ≈ $354,096, broken out as:
- 7,003 shares at a weighted average ≈ $36.25 (sale proceeds $253,852) — sale prices ranged $35.61–$36.60 (F1).
- 1,671 shares at a weighted average ≈ $36.80 (sale proceeds $61,489) — sale prices ranged $36.62–$37.11 (F2).
- 1,026 shares at a weighted average ≈ $37.77 (sale proceeds $38,755) — sale prices ranged $37.69–$38.35 (F3).
- Net cash received (proceeds minus exercise cost) ≈ $186,771.
- Shares owned after the transactions: not specified in the provided filing.
- Footnotes: sales reported as weighted averages across multiple execution prices (F1–F3); options vesting schedule noted (F4: three equal annual installments on first business days of Sept 2025, 2026, 2027). The filer offers to provide detailed per-price allocation on request.
Context
This was an option exercise immediately followed by market sales (a common cashless-like transaction). The activity is factual reporting of converting and disposing of shares; it does not, by itself, indicate management sentiment. For more detail on outstanding holdings or total insider ownership, consult the company’s full Form 4 or related filings.
Insider Transaction Report
- Exercise/Conversion
Common Stock
2026-06-08$17.25/sh+9,700$167,325→ 157,451 total - Sale
Common Stock
[F1]2026-06-08$36.25/sh−7,003$253,852→ 150,448 total - Sale
Common Stock
[F2]2026-06-08$36.80/sh−1,671$61,489→ 148,777 total - Sale
Common Stock
[F3]2026-06-08$37.77/sh−1,026$38,755→ 147,751 total - Exercise/Conversion
Employee Stock Option (right to buy)
[F4]2026-06-08−9,700→ 19,400 totalExercise: $17.25Exp: 2034-09-03→ Common Stock (9,700 underlying)
Footnotes (4)
- [F1]Reflects the weighted average price of 7,003 shares of common stock of Electromed, Inc. sold by the reporting person in multiple transactions on June 8, 2026 with sale prices ranging from $35.61 to $36.60 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F2]Reflects the weighted average price of 1,671 shares of common stock of Electromed, Inc. sold by the reporting person in multiple transactions on June 8, 2026 with sale prices ranging from $36.62 to $37.11 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Reflects the weighted average price of 1,026 shares of common stock of Electromed, Inc. sold by the reporting person in multiple transactions on June 8, 2026 with sale prices ranging from $37.69 to $38.35 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Options scheduled to vest and become exercisable in three equal annual installments on each of the first business days of September 2025, 2026 and 2027.